Nexthera Capital LP boosted its position in shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) by 50.0% during the first quarter, Holdings Channel reports. The institutional investor owned 150,000 shares of the specialty pharmaceutical company’s stock after buying an additional 50,000 shares during the period. Paratek Pharmaceuticals makes up approximately 1.5% of Nexthera Capital LP’s investment portfolio, making the stock its 18th largest position. Nexthera Capital LP owned about 0.55% of Paratek Pharmaceuticals worth $2,888,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in PRTK. Vanguard Group Inc. raised its position in shares of Paratek Pharmaceuticals by 9.5% in the first quarter. Vanguard Group Inc. now owns 724,300 shares of the specialty pharmaceutical company’s stock worth $13,942,000 after buying an additional 63,121 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Paratek Pharmaceuticals by 275.9% in the first quarter. Renaissance Technologies LLC now owns 414,513 shares of the specialty pharmaceutical company’s stock worth $7,979,000 after buying an additional 304,249 shares in the last quarter. General American Investors Co. Inc. raised its position in shares of Paratek Pharmaceuticals by 16.7% in the first quarter. General American Investors Co. Inc. now owns 307,213 shares of the specialty pharmaceutical company’s stock worth $5,914,000 after buying an additional 44,037 shares in the last quarter. State Street Corp raised its position in shares of Paratek Pharmaceuticals by 21.5% in the fourth quarter. State Street Corp now owns 238,092 shares of the specialty pharmaceutical company’s stock worth $3,668,000 after buying an additional 42,117 shares in the last quarter. Finally, MARSHALL WACE ASIA Ltd purchased a new position in shares of Paratek Pharmaceuticals during the first quarter worth $3,258,000. 75.99% of the stock is currently owned by institutional investors and hedge funds.
Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) traded down 1.79% during mid-day trading on Thursday, hitting $22.00. The stock had a trading volume of 406,382 shares. The firm has a 50 day moving average price of $21.59 and a 200 day moving average price of $17.62. Paratek Pharmaceuticals, Inc. has a 52-week low of $9.80 and a 52-week high of $25.00. The firm’s market cap is $604.67 million.
Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its earnings results on Thursday, May 4th. The specialty pharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.06. The company had revenue of $0.02 million during the quarter.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Mideast Time and is the property of of Mideast Time. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.mideasttime.com/nexthera-capital-lp-raises-position-in-paratek-pharmaceuticals-inc-prtk/1784190.html.
PRTK has been the topic of a number of research reports. Zacks Investment Research raised Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a report on Thursday, April 20th. Robert W. Baird reissued a “positive” rating and issued a $40.00 price objective on shares of Paratek Pharmaceuticals in a report on Monday, March 27th. Guggenheim reissued a “buy” rating on shares of Paratek Pharmaceuticals in a report on Monday, March 27th. Raymond James Financial, Inc. started coverage on Paratek Pharmaceuticals in a research note on Thursday, May 18th. They issued a “strong-buy” rating and a $36.00 target price on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $32.00 target price on shares of Paratek Pharmaceuticals in a research note on Thursday, March 30th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Paratek Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $36.80.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Want to see what other hedge funds are holding PRTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK).
Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.